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statistically signiﬁ  cantly different CSF KYNA levels, i.e. 
2.84   8   0.16 fmol/    l vs. 4.09   8   0.14 fmol/ l, p   !   0.001, 
respectively; but this difference was not seen in serum 
samples. Interestingly, KYNA is synthesised in CSF prin-
cipally by KAT I and not KAT II, however no relationship 
was found between enzyme activity and ageing. A posi-
tive relationship between CSF KYNA levels and age of 
subjects indicates a 95% probability of elevated CSF 
KYNA with ageing (R = 0.6639, p = 0.0001). KYNA levels 
signiﬁ  cantly correlated with IgG and       2 -microglobulin 
levels (R = 0.5244, p = 0.0049; R = 0.4253, p = 0.043, re-
spectively). No correlation was found between other bi-
ological parameters in CSF or serum. In summary, a pos-
itive relationship between the CSF KYNA level and ageing 
was found, and the data would suggest age-dependent 
increase of kynurenine metabolism in the CNS. An en-
hancement of CSF IgG and       2 -microglobulin levels would 
suggest an activation of the immune system during age-
ing. Increased KYNA metabolism may be involved in the 
hypofunction of the glutamatergic and/or nicotinic cho-
linergic neurotransmission in the ageing CNS. 
  Copyright © 2005 S. Karger AG, Basel 
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    Abstract 
  Kynurenic acid (KYNA) is an endogenous metabolite in 
the kynurenine pathway of tryptophan degradation and 
is an antagonist at the glycine site of the N-methyl-  D  -as-
partate as well as at the alpha 7 nicotinic cholinergic re-
ceptors. In the brain tissue KYNA is synthesised from 
  L  -kynurenine by kynurenine aminotransferases (KAT) I 
and II. A host of immune mediators inﬂ  uence tryptophan 
degradation. In the present study, the levels of KYNA in 
cerebrospinal ﬂ  uid (CSF) and serum in a group of human 
subjects aged between 25 and 74 years were determined 
by using a high performance liquid chromatography 
method. In CSF and serum KAT I and II activities were 
investigated by radioenzymatic assay, and the levels of 
      2 -microglobulin, a marker for cellular immune activa-
tion, were determined by ELISA. The correlations be-
tween neurochemical and biological parameters were 
evaluated. Two subject groups with signiﬁ  cantly differ-
ent ages, i.e.   !  50 years and   1  50 years, p   !   0.001, showed 
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  Introduction 
  Glutamate  is  an  important  metabolic  agent  in  the 
mammalian central nervous system (CNS), and its exci-
totoxic activity has been proposed to contribute to the 
pathogenesis of various CNS disorders in humans   [1–3]  . 
Kynurenic acid (KYNA) is a well-known endogenous an-
tagonist  of  the  glutamate  ionotropic  excitatory  amino 
acid  receptors  N-methyl-  D  -aspartate  (NMDA),  alpha-
amino-3-hydroxy-5-methylisoxazole-4-propionic  acid 
and kainate   [4]   and of the nicotine cholinergic subtype 
alpha 7 receptors   [5]  , and KYNA neuroprotective and 
anticonvulsive activities have been demonstrated in ani-
mal models of neurodegenerative diseases   [6, 7]  . Because 
of KYNA’s neuromodulatory character, its involvement 
has been speculatively linked to the pathogenesis of a 
number of neurological conditions including those in the 
ageing process. 
  Different patterns of abnormalities in various stages 
of KYNA metabolism in the CNS have been reported in 
Alzheimer’s disease   [8]  , Parkinson’s disease   [9]   and Hun-
tington’s disease   [10–12]  . In HIV-1-infected patients   [13]   
and in patients with Lyme neuroborreliosis   [14]   a marked 
rise of KYNA metabolism was seen. 
  In the ageing process KYNA metabolism in the CNS 
of rats shows a characteristic pattern of changes through-
out the life span   [15–18]  . A marked increase of the KYNA 
content in the CNS occurs before the birth, followed by 
a dramatic decline on the day of birth   [16]  . A low activ-
ity was seen during ontogenesis   [15]  , and a slow and pro-
gressive enhancement occurs during maturation   [15]   and 
ageing   [17]  . This remarkable proﬁ  le of KYNA metabo-
lism alterations in the mammalian brain has been sug-
gested to result from the development of the organisation 
of neuronal connections and synaptic plasticity, develop-
ment of receptor recognition sites, maturation and ageing 
  [4]  .  
  There is signiﬁ  cant evidence that KYNA can improve 
cognition and memory   [19]  , but it has also been demon-
strated that it interferes with working memory   [20]  . Im-
pairment of cognitive function in various neurodegen-
erative disorders is accompanied by profound reduction 
and/or elevation of KYNA metabolism. The view that 
enhancement of CNS KYNA levels could underlie cogni-
tive decline is supported by the increased KYNA metab-
olism in Alzheimer’s disease   [8]  , by the increased KYNA 
metabolism in Down’s syndrome   [21]   and the enhance-
ment of KYNA function during the early stage of Hun-
tington’s disease   [11]  . In 1999, Baran et al.   [8]   suggested 
that the blocking of the glutamatergic neurotransmission 
in Alzheimer’s disease patients due to increased CNS 
KYNA levels could be involved in memory and cognition 
impairments. Since KYNA can block both glutamatergic 
  [4]   and the alpha 7 nicotinic cholinergic activities   [5]  , it 
is reasonable to speculate that the ﬂ  uctuation of KYNA 
metabolism could signiﬁ  cantly inﬂ  uence both. The po-
tency of KYNA as a nicotinic antagonist is similar to its 
potency as an antagonist at the glycine site of NMDA re-
ceptors   [22]  . The recent memory deﬁ  cit and/or hypofunc-
tion  of  neurotransmission    [3]    and  hyperfunction  of 
KYNA   [8]   may reﬂ  ect as a key event, which could share 
several important elements in dementia of Alzheimer and 
ageing as well.  
    L  -kynurenine is the primary metabolite of the enzy-
matic degradation of tryptophan by indoleamine-2,3-di-
oxygenase (IDO). An interaction between glial and im-
mune cells through the release of cytokines has been de-
scribed in many pathological conditions, and the secretion 
of cytokines, such as interferon-    , interleukin-1 and 6, 
tumor necrosis factor-    , in response to injury and infec-
tion play a prominent role in the initiation and mainte-
nance of neurotoxic immune responses within the injured 
CNS and further propagate CNS damage   [23–26]  . Acti-
vation of IDO by interferon-     has been observed in hu-
man monocytes/macrophages and a variety of human 
cells and cell lines in vitro   [27, 28]  .       2 -Microglobulin, a 
marker of activation of immune cells, is a small protein 
associated with the class I major histocompatibility com-
plex antigen. Increasing       2 -microglobulin levels are con-
sidered to reﬂ  ect an activation of the cellular immune 
system and enhancement in cell membrane turnover   [29, 
30]  . Several disorders of the CNS are associated with in-
creased cerebrospinal ﬂ  uid (CSF)       2 -microglobulin lev-
els, such as in Alzheimer type dementia   [31]  , brain infarct 
and meningitis   [32]   and HIV infection   [33]  . A positive 
correlation between increase of kynurenine metabolites 
and       2 -microglobulin levels in CSF and serum has been 
reported in HIV type 1 infection   [13]  . In the present study 
we asked whether KYNA metabolism and markers of the 
immune system undergo alterations in the CSF and se-
rum of human subjects without neurological disease but 
with advancing age. We analysed the correlation between 
changes of KYNA metabolism and biological parameters 
in CSF and serum in order to ﬁ  nd indications for relation-
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      Materials and Methods 
  Materials 
    L  -kynurenine, KYNA and pyridoxal-5    -phosphate were pur-
chased  from  Sigma.  [  3 H]  L  -kynurenine  (speciﬁ  c  activity,  41  Ci/
mmol) was supplied by Amersham, England. Rabbit anti-human 
IgG, rabbit anti-human IgM and rabbit anti-human albumin were 
obtained from Dade Behring, Turbiquant Germany. The       2 -Micro-
globulin ELISA KIT was obtained from Instrumentation Labora-
tory GmbH, Austria. All other chemicals used were of the highest 
commercially available purity. 
      Subjects 
  Out of a larger series of acute headache patients who underwent 
lumbar puncture to exclude subarachnoidal haemorrhage or viral 
or bacterial meningitis, 27 individuals were selected for this study 
because CSF samples from these patients did not contain erythro-
cytes, and no abnormalities in neuroimaging and further clinical 
investigations, which included in most cases electroencephalogra-
phy and transcranial Doppler sonography, were found. All of these 
investigated individuals were not treated with analgesic drugs pri-
or to the lumbar puncture and following investigation conﬁ  rmed a 
normal clinical status. Ages ranged between 25 and 74 years. Lum-
bar puncture was carried out to obtain CSF for routine parameter 
determinations, as e.g. number of erythrocytes, cell count, protein 
content and detection of IgG oligoclonal bands, autochtonic im-
munoglobulin production IgG index and albumin content. Blood 
samples were taken for routine investigation of leukocyte count, 
IgG and IgM and albumin content. For neurochemical analyses 
samples of CSF and serum were collected immediately in 1-ml ali-
quots and stored at –30    °    C until analysed. CSF and serum were 
coded to make anonymous and the study was carried out according 
to the ethical regulations of Lower Austria. 
      Investigations of the Biological Parameters 
  Measurement of protein, albumin, IgG, IgM and white blood 
cell counts were carried out using routine laboratory methods. CSF:
serum IgG ratio and CSF:serum albumin ratio and the IgG index 
were calculated   [34]  . For determination of oligo  clonal IgG bands, 
agarose isoelectric focusing was performed, followed by transfer to 
cellulose nitrate membrane and double antibody avidin-biotin-per-
oxidase labelling   [35]  . 
      Neuroradiological Investigations 
  Routine clinical investigations of cranial computer tomography 
and magnetic resonance tomography with computer tomography 
or MR angiography of cerebral vessels, and electroencephalography 
and transcranial Doppler sonography were carried out. 
      Measurement of KYNA 
  The measurement of KYNA was performed according to Shi-
bata   [36]   and Swartz et al.   [37]   with modiﬁ  cation described by Ba-
ran et al.   [8]  . Brieﬂ  y, CSF or serum samples were mixed with
0.2   M   HCl (vol/vol) and centrifuged (20 min, 14,000 rpm). The 
supernatant was applied to a Dowex 50W cation exchange column 
pre-washed with 0.1   M   HCl. Subsequently, the column was washed 
with 0.1       M   HCl and 1 ml distilled water, and KYNA was eluted 
with 2 ml distilled water   [38]   and was quantitated by high perfor-
mance liquid chromatography system coupled with ﬂ  uorescence 
detection.  
      Measurement of Kynurenine Aminotransferases I and II in 
CSF and Serum 
  Measurement of of kynurenine aminotransferases (KAT) I and 
II activities in CSF and serum was performed using a radioenzy-
matic assay described by Schmidt et al.   [39]  . In brief, the reaction 
mixture contained CSF or serum, 100       M   1.175     Ci/    mol [  3 H]  L  -
kynurenine, 1 m  M   pyruvate, 70       M   pyridoxal-5    -phosphate and 
150 m  M   2-amino-2-methyl-l-propanol buffer pH 9.6 for KAT I in 
a  total  volume  of  200      l.  For  KAT  II  activity  measurement
150 m  M   Tris-acetate buffer pH 7.0 was used. The measurement of 
KAT II activity was performed in the presence and absence of 
5 m  M     L  -glutamine. After incubation for 16 h at 37    °    C, the reaction 
was stopped by adding 14     l of 50% trichloroacetic acid and 1 ml 
of 0.1   M   HCl. Denatured proteins were removed by centrifugation, 
and the synthesised [  3 H]KYNA was puriﬁ  ed on Dowex 50W cation 
exchange column   [38]   and quantiﬁ  ed by liquid scintillation spec-
trometry. Blanks were prepared by boiling CSF or serum samples 
for 15 min before adding the reaction mixture. 
      Measurement of        2 -Microglobulin in CSF and Serum 
        2 -Microglobulin concentration in CSF and serum was mea-
sured by using a commercial sandwich ELISA method. 
      Statistical Analysis 
  All mean values   8   SEM are given. For statistical signiﬁ  cance 
the one-way ANOVA and Student’s t test were applied. Linear re-
gression analysis was performed using the least squares method. 
Correlation between clinical parameters, e.g. CSF IgG, IgG index, 
CSF KYNA levels, serum KYNA levels and KAT activities with 
ageing was analysed. The levels for statistical signiﬁ  cance were tak-
en as p   !   0.05. 
      Results 
  Biological Parameters 
  Two groups of human subjects of signiﬁ  cantly differ-
ent ages (age   !  50 and age   1  50) were evaluated. The mean 
age of the groups was 35.4   8   2.2 years, ranging from 25 
to 50 years, and 61.6   8   3.3 years, ranging from 50 to 74 
years, and the difference between both groups was sig-
niﬁ  cant, i.e. p     !     0.001 (  table 1  ). The values of CSF IgG, 
the CSF:serum IgG ratio and       2 -microglobulin in CSF 
were signiﬁ  cantly higher in subjects of the   1  50 years age 
group (  table 1  ). A moderate increase of protein levels in 
CSF and of the CSF:serum albumin ratio was observed 
of the   1  50 years age group. No signiﬁ  cant differences re-
garding parameters could be found in the serum. 
      Correlation between Biological Parameters 
  Using a linear regression analysis it could be observed 
that with increasing age of the subjects the CSF IgG val-
ues also increased signiﬁ  cantly (  ﬁ  g. 1  ; R = 0.4582, p = 
0.0146). However, no positive correlation was found be-
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0.1301).  Subsequently,  signiﬁ  cant  correlation  was  ob-
tained between the value of CSF IgG and the IgG index 
(  ﬁ  g. 2  ; R = 0.5556, p = 0.0026). A moderate positive re-
lationship was found between the CSF:serum albumin 
ratio and age and between CSF:serum IgG ratio and age 
(R = 0.3644, p = 0.0873; R = 0.3552, p = 0.0690, respec-
tively). 
      KYNA Levels in CSF and Serum 
  In all subjects aged from 25 to 74 years the mean val-
ue of KYNA levels in CSF and in the serum was 3.30   8   
0.17 and 26.54   8   1.87 fmol/    l, respectively. In the   1  50 
years age group the level of CSF KYNA was signiﬁ  cantly 
higher (p   !   0.001) than in subjects of the age   !  50 years, 
but no differences could be found in the sera (  ﬁ  g. 3  ). With-
Table 1. Biological parameters of subjects
Biological parameters Age, years Age >50,
% of age <50
25–74 (n = 27) <50 (n = 17) >50 (n = 10) 
Number of leukocytes, 106/l 6.4980.37 6.6280.40 6.2680.78  95
IgG serum, mg/dl 923.7849.7 940.9871.0 891.4856.8  95
IgM serum, mg/dl 81.187.0 84.988.6 74.0812.6  87
Proteins in CSF, mg/dl 33.981.7 32.282.1 36.883.0  114
Cell count, !106/l 2.7180.24 2.5180.26 2.9180.22  116
Oligoclonal IgG bands negative negative negative  100
IgG CSF, mg/dl 1.9480.13 1.6980.15 2.3680.21**  140
Ratio CSF:serum IgG 2.1580.17 1.8980.21 2.5880.24*  137
Ratio CSF:serum albumin  4.0080.26 3.6680.35 4.5980.30  125
IgG index 0.52480.013 0.50680.014 0.55480.022  109
CSF  2-Microglobulin in CSF, mg/l 1.2080.08 1.0280.39 (14) 1.4780.14** (9)  144
 2-Microglobulin in serum, mg/l 3.0180.27 3.1480.32 (16) 2.7380.53 (7) 87
Age, years 45.183.0 35.482.2 61.683.3*** 174
Females/males 12/15 7/10 5/5
Data represent mean 8 SEM. Number of subjects is given in parentheses. 
* p < 0.05; ** p < 0.01; *** p < 0.001 vs. group with age <50 years using Student’s t test.






























  Fig. 1. Linear regression analysis between CSF IgG values and age 
in human subjects.  





























    Fig. 2.   Linear regression analysis between CSF IgG values and IgG 
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in each group no inﬂ  uence of sex on CSF KYNA levels 
was found.  
      Kynurenine Aminotransferase I and II 
  Using a radioenzymatic assay we measured formation 
of KYNA from   L  -kynurenine in CSF and less in serum. 
Using assay condition for KAT I and II the conversion of 
  L  -kynurenine to KYNA was 155.2   8   20.3 and 19.2   8   
4.3 KYNA fmol/    l/h, respectively. However, in 9 CSF 
samples of 27 no formation of KYNA (negative value) 
was seen using KAT I reaction conditions, and in remain-
ing  samples  the  results  ranged  between  35  and  346.5 
KYNA fmol/    l/h. The KAT II activity in CSF ranged 
between 2.4 and 34.0 KYNA fmol/    l/h and in 19 samples 
no formation of KYNA (negative value) was measured. 
In the presence of 5 m  M   glutamine KAT II activity was 
moderately reduced to 15.4   8   2.9 KYNA fmol/    l/h. The 
value of KAT II in the presence of 5 m  M   glutamine ranged 
between 5.0 and 29.3 KYNA fmol/    l/h and in 17 CSF 
probes no formation was seen (negative value). Using as-
say condition for KAT I and II, in all serums the conver-
sion was less than 2 fmol/    l/h or there was no formation 
of KYNA.  
      Correlation between Kynurenine Metabolism and 
Biological Parameters 
  A positive relationship was found between CSF KYNA 
levels and advancing age, indicating a 95% probability of 
increasing CSF KYNA levels with age (  ﬁ  g. 4  ; R = 0.6639, 
p   !   0.0001). No positive relationship between both pa-
rameters was measured in the serum (R = 0.1118, p = 
0.6114). A comparison between CSF KYNA and CSF 
IgG levels revealed a signiﬁ  cantly positive relationship 
(  ﬁ  g. 5  ; R = 0.5244, p = 0.0049). No positive correlation 
was seen between CSF KYNA levels and the IgG index 
(R = 0.1898, p = 0.343), between CSF KYNA levels and 


































Fig. 3. KYNA in CSF and serum in two subject groups, i.e. age
  !  50 years (n = 17) and age   1  50 years (n = 10). Signiﬁ  cance between 
both groups was *** p   !   0.0001.













































            Fig. 4.   Linear regression analysis between CSF KYNA concentra-
tion and age in human subjects.  
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    Fig. 5.   Linear regression analysis between CSF KYNA concentra-
tion and CSF IgG level in human subjects. 
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tween CSF KYNA and ratio serum:CSF albumin (R = 
0.3057, p = 0.1210). No correlation could be found be-
tween KAT activities and biological parameters. 
  In the CSF but not in the serum signiﬁ  cant differences 
between two subject groups (age   !  50 vs. age   1  50) could 
be observed regarding the       2 -microglobulin level (  table 
1  ). A positive correlation was found between CSF       2 -mi-
croglobulin and ageing, whereas no correlation was seen 
between serum       2 -microglobulin and ageing (  ﬁ  g. 6  ; R = 
0.5671, p = 0.005 and R = –0.039, p = 0.8564), respec-
tively. Furthermore, a positive relationship was found 
between CSF KYNA and       2 -microglobulin levels, and a 
moderate relationship was found between CSF IgG and 
      2 -microglobulin concentrations (  ﬁ  g. 7  ; R = 0.4253, p = 
0.0430 and R = 0.3866, p = 0.0684, respectively). No 
positive relationship was found between serum       2 -micro-
globulin and serum IgG (R = 0.357, p = 0.0939), between 
serum       2 -microglobulin and serum IgM (R = 0.0327, p = 
0.8823) and between serum       2 -microglobulin and serum 
KYNA levels (R = 0.1256, p = 0.5679). 
      Discussion 
  The most notable ﬁ  nding of the study is that in the CSF 
of human subjects without detectable neurological dis-
ease, the KYNA level signiﬁ  cantly increase with advanc-
ing age. In addition, with advancing age, the levels of im-








p = 0.8564 
R =   0.039
















































Fig. 6. Correlation between CSF       2 -micro-
globulin levels and age (S), and lack of cor-
relation  between  serum        2 -microglobulin 
levels and age (  $  ) in human subjects.
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            Fig. 7.    Correlation  between  CSF  KYNA 
and CSF       2 -microglobulin concentrations 
(S) and between CSF IgG and CSF       2 -mi-
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munoreactive markers IgG and       2 -microglobulin were 
increasing, whereas no increase of KYNA,       2 -microglob-
ulin or IgG was found in the serum. Interestingly, Heyes 
et al.   [40]   observed higher CSF KYNA levels (3.49   8   0.44 
vs. 2.23   8   0.28 n  M  ) and higher CSF   L  -kynurenine levels 
(52.9   8   3.1 vs. 33.2   8   2.8 n  M  ) in older control subjects 
(59.1   8   14.2 vs. 35.2   8   8.4 years, respectively). Further-
more, in line with our data, another research group has 
found that in childhood levels of CSF IgG also were sig-
niﬁ  cantly different from adult reference readings   [41]  . 
The increase of CSF KYNA with ageing has been report-
ed in sheep as well   [42]  . Revealed data would suggest the 
age-related increase of KYNA in human CSF and the in-
volvement of increased immune markers. 
  Recently, Erhardt et al.   [43]   demonstrated increased 
CSF KYNA with ageing in schizophrenia patients, but no 
correlation was found in healthy volunteers, probably due 
to a narrow age range (between 22 and 44 years) of healthy 
volunteers investigated. The mean of CSF KYNA values 
of subjects investigated in the present study was 3.3   8   
0.17 n  M  . Accumulated data on CSF KYNA levels in 
healthy volunteers/control subjects indicate a wide varia-
tion of concentration (between 0.67 and 4.09 n  M  )   [7, 40, 
43, 44]  . Several previously published papers suggested a 
connection between increase of CSF KYNA and pain
  [37,  45]  .  Indeed,  Swartz  et  al.    [37]    found  high  CSF
KYNA levels in patients with fever or headache (5.09   8   
1.04 n  M  ). Interestingly, analgesic drugs are also able to 
modify the KYNA concentration; however, the mecha-
nism of increasing KYNA levels due to pain and its action 
to modulate pain needs to be more clariﬁ  ed   [46]  .  
  KYNA content measured in CSF depends on differ-
ently regulated events involved in KYNA metabolism, 
such as substrate availability, uptake, its formation and 
release into CSF and diffusion into the blood   [4, 18, 38, 
47, 48]  . In adult animals KYNA does not or very slightly 
penetrates through the blood-brain barrier (BBB)   [49]  . 
With increasing age of the subjects analysed, a moderate 
increase of BBB permeability was observed in line with 
previously published data   [50]  , and a slightly positive re-
lationship between CSF:serum albumin concentrations 
ratio and ageing or CSF KYNA levels would not exclude 
a very moderate diffusion of KYNA into the aged CNS. 
Since no difference in KYNA serum level was found in 
subjects investigated, we would suggest that CSF KYNA 
increases with advancing age originate from the brain. In 
this connection, in the rat brain but not in the rat liver, 
the KYNA metabolism was signiﬁ  cantly increased with 
advanced age, as well   [17]  .  
  In the CNS, KYNA may derive from   L  -kynurenine 
that was synthesised either by CNS tissue following IDO, 
the ﬁ  rst enzyme of the kynurenine pathway in extrahe-
patic tissue, or from   L  -kynurenine that had entered from 
blood   [51]  . Interestingly, the   L  -kynurenine was shown to 
be signiﬁ  cantly higher in the CSF of healthy aged rats   [52]   
and in older human control subjects too   [40]  . Further-
more, those authors   [51]   have also demonstrated that the 
ratio of   L  -kynurenine:tryptophan was doubled in aged 
rats  (28–32  months),  comparing  to  mature  rats  (4–6 
months), and suggested age-related activation of IDO ac-
tivities. Similar changes might occur in the human brain, 
for example due to the induction of enzyme IDO activi-
ties. Human macrophages express IDO activities, and the 
enzyme is sensitive to interferon-       [53]  . A signiﬁ  cant in-
crease of kynurenine pathway enzyme activities due to 
interferon-     stimulation was demonstrated in blood mac-
rophages, astrocytes, neurones and also B lymphocyte 
  [54]  . No data are currently available about interferon-     
formation in the human CNS during the ageing process.  
  In the human brain KYNA is synthesised from   L  -kyn-
urenine by KAT I and KAT II   [39, 55, 56]  . Both proteins 
show distinct catalytic properties, e.g. KAT I has a pH 
optimum of 9.5–10, while KAT II displays a pH optimum 
of 7.4   [39, 55, 56]  . In contrast to KAT II, KAT I shows 
particular preferences for amino acceptors and is inhib-
ited by millimolar concentrations of   L  -amino acids, e.g. 
  L  -glutamine,   L  -phenylalanine and   L  -tryptophan   [39, 56]  . 
The cellular localisation of human brain KAT I and KAT 
II has not been demonstrated so far, whereas in the rat 
brain KAT antibodies used in immunohistological stud-
ies demonstrated a preferential astrocyte localisation of 
the protein   [57]  . 
  Interestingly, in animal studies using in situ hybridi-
sation it has been shown recently that the KAT I mRNA 
activity is expressed not only in the mitochondria of neu-
rone and glial cells but also in the cytosol of the choroid 
plexus epithelial cells   [58]  . It is therefore reasonable to 
believe that the synthesis of KYNA also may take place 
in the choroid plexus due to KAT I activity, and synthe-
sised KYNA is released into CSF and/or speculatively 
due to changes of the choroid plexus membrane the KAT 
proteins (or cells) from cytosol could easily diffuse into 
CSF. Indeed, in our previous   [59]   and in present study 
we measured in some CSF probes a moderate formation 
of KYNA, due to KAT I activity, but in some we found 
a negative value. Human KAT I is sensitive to amino ac-
ids   [39, 56]   and KAT I inhibition in the CSF was seen in 
the presence of 5 m  M   glutamine. In human, the CSF ami-
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was observed in aged brain   [60]  . There could not be found 
any correlations between CSF KAT activities and other 
parameters.  
  An important pathological feature of a variety of neu-
rological disorders, including the normal ageing process 
of the brain, is the activation of microglia. It has been 
suggested that the activation of microglia in white matter 
with advancing age may play a substantial role in the 
pathogenesis of normal brain ageing   [61]  . The increases 
of KYNA in the CSF during ageing could take place due 
to elevated KATs expression/activities in microglia and 
astrocytes as well. The latter cells are also immunorespon-
sive within the CNS   [57]  . Immunohistopathological stud-
ies indicate a predominantly astrocytic localisation of 
KAT in rat brains   [57]   and the major constituent of in-
termediate ﬁ  laments in astrocytes, glial ﬁ  brillary acidic 
protein is increased with progressing age   [62]  . Astrocytes 
provide a variety of endogenous signals and diffusible 
factors that may serve to induce the formation of tight 
junctions, the expression of various proteins, maintain 
overall BBB integrity and promote differentiation and 
maturation of microglia   [26, 63]  . A large body of evidence 
now exists which implicates excessive microglia activa-
tion and proliferation in the development of neuronal 
death in various pathological disease states and in ageing 
process   [63, 64]  . At least in animal studies, experiments 
on KYNA synthesis with neuron-depleted rat brain tis-
sue, which exhibits markedly elevated KYNA formation 
at a time of pronounced astrogliosis, suggest that astroglia 
are responsible for de novo formation of brain KYNA 
  [38]  . 
  Interestingly, Morgan et al.   [65]   showed that food re-
striction  decreased  the  transcription  of  glial  ﬁ  brillary 
acidic protein in ageing rats and lowered microglia acti-
vation during ageing. A sparing of spatial memory can be 
achieved with applied diet restriction and the effect of 
ageing on NMDA receptor is associated with age-related 
declines in spatial memory   [66]  . The increases of IgG and 
      2 -microglobulin levels in the CSF during ageing can oc-
cur due to immune system activation. A positive relation-
ship was found between both parameters. The age-related 
increase of CSF KYNA levels, IgG content and       2 -micro-
globulin concentration is of particular interest with re-
spect to the ability to block NMDA and cholinergic alpha 
7 receptors by drugs that activate tryptophan metabo-
lism. In this connection, the CSF       2 -microglobulin level 
is  signiﬁ  cantly  higher  in  Alzheimer’s  disease  patients 
  [31]  . The binding site of the NMDA receptor antagonist 
is signiﬁ  cantly reduced in 30-month-old mice, which in-
dicates an age-related decline of neuronal response   [66–
68]  . KYNA not only blocks the NMDA receptors   [4]  , but 
also the alpha 7 subtype of nicotine cholinergic receptors 
  [5]  . The increase of CSF KYNA with ageing and the in-
crease of KYNA metabolism in the CNS of Alzheimer’s 
disease patients   [8]   would suggest a long-lasting blockade 
of  glutamatergic  and  cholinergic  neurotransmission, 
events that are involved in the pathogenesis of memory 
and cognitive impairments   [3]  . Therefore, the activation 
of tryptophan/kynurenine metabolism in aged persons 
and Alzheimer’s disease patients may result in a negative 
response(s). An alteration of the receptor activities due to 
the ageing process may involve changes in KYNA me-
tabolism and probably both processes could reciprocate. 
  In summary, increases in CSF KYNA, IgG and       2 -mi-
croglobulin levels have been identiﬁ  ed in subjects of ad-
vanced age, and the data obtained would suggest the hy-
poglutamatergic  and  hypocholinergic  stages  in  aged 
brains. Further studies need to be accomplished in order 
to provide more information on the mechanism(s) of di-
rect and/or indirect KYNA action and its involvement in 
the memory and cognition impairment during ageing. 
The relationship between KYNA changes and activation 
of IgG and       2 -microglobulin levels with ageing is not yet 
clear. 
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